Stay updated on ARGX-110 with Azacytidine in AML Clinical Trial
Sign up to get notified when there's something new on the ARGX-110 with Azacytidine in AML Clinical Trial page.

Latest updates to the ARGX-110 with Azacytidine in AML Clinical Trial page
- Check5 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3.SummaryDifference0.1%

- Check12 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedSite update adds Revision: v3.4.2 and removes the government funding status notice (Revision: v3.4.1).SummaryDifference0.4%

- Check41 days agoChange DetectedAdded a government funding notice about potential delays and updated operations status information with a link to opm.gov. Updated the site revision from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check48 days agoChange DetectedGlossary toggle added; QC-related metadata updated to 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0', replacing the prior QC label and version, and a 'No FEAR Act Data' item is now shown instead of the former 'No FEAR Act data' entry.SummaryDifference0.2%

- Check62 days agoChange DetectedThe page displays Revision: v3.3.4, replacing Revision: v3.3.3.SummaryDifference0.1%

- Check83 days agoChange DetectedFooter changes include removal of the HHS Vulnerability Disclosure link and addition of a site revision label 'Revision: v3.3.3' (replacing 'Revision: v3.3.2'). To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to ARGX-110 with Azacytidine in AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ARGX-110 with Azacytidine in AML Clinical Trial page.